Proefschrift

CHAPTER 2.1 30 REFERENCES 1. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM-W, Barlinn K, Siepmann T. Randomized controlled trials – a matter of design. Neuropsychiatr Dis Treat 2016;12:1341–1349. 2. Rothwell PM. External validity of randomised controlled trials: ‘to whom do the results of this trial apply?’ Lancet Lond Engl 2005;365:82–93. 3. Dekkers OM, Elm E von, Algra A, Romijn JA, Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol 2010;39:89–94. 4. Lesko CR, Buchanan AL, Westreich D, Edwards JK, Hudgens MG, Cole SR. Generalizing Study Results: A Potential Outcomes Perspective. Epidemiol Camb Mass 2017;28:553–561. 5. Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015;16:495. 6. Lenzen MJ, Boersma E, Reimer WJMSO, Balk AHMM, Komajda M, Swedberg K, Follath F, JimenezNavarro M, Simoons ML, Cleland JGF. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. Eur Heart J 2005;26:2706–2713. 7. Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, Mair FS, Guthrie B, Wild S, McAllister DA. Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. BMC Med 2019;17:201. 8. Miró Ò, Gil V, Müller C, Mebazaa A, Bueno H, Martín-Sánchez FJ, Herrero P, Jacob J, Llorens P. How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry. Clin Res Cardiol Off J Ger Card Soc 2015;104:850–860. 9. Patel HC, Hayward C, Dungu JN, Papadopoulou S, Saidmeerasah A, Ray R, Di Mario C, Shanmugam N, Cowie MR, Anderson LJ. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a ‘Pure’ Patient Phenotype and the Generalizability of Trial Findings. J Card Fail 2017;23:517–524. 10. Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. Eur J Heart Fail 2019;21:1383–1397. 11. Innovative Medicines Initiative. BigData@Heart. IMI Innov. Med. Initiat. 2021. http://www.imi.europa.eu/projects-results/project-factsheets/bigdataheart (7 September 2021) 12. Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006;152:860–866. 13. Swedberg K, Komajda M, BöhmM, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75– 81. 14. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Mori C, Eisenhart Rothe B von, Pocock S, Poole-Wilson PA, Ponikowski P, FAIR-HF committees and investigators. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084–1091.

RkJQdWJsaXNoZXIy MjY0ODMw